Steph & Co. Sells 3,009 Shares of Pfizer Inc. (NYSE:PFE)

Steph & Co. trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 25.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 8,672 shares of the biopharmaceutical company’s stock after selling 3,009 shares during the quarter. Steph & Co.’s holdings in Pfizer were worth $250,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the business. Moneta Group Investment Advisors LLC lifted its holdings in shares of Pfizer by 89,592.7% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after acquiring an additional 160,963,976 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Pfizer by 10.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock valued at $3,161,261,000 after buying an additional 9,393,992 shares during the last quarter. Morgan Stanley raised its holdings in Pfizer by 0.4% during the 3rd quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock valued at $2,817,055,000 after buying an additional 348,628 shares during the last quarter. Norges Bank bought a new stake in Pfizer during the 4th quarter valued at $3,150,472,000. Finally, Massachusetts Financial Services Co. MA raised its holdings in Pfizer by 9.4% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 60,207,521 shares of the biopharmaceutical company’s stock valued at $1,997,083,000 after buying an additional 5,185,453 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

PFE has been the subject of a number of recent analyst reports. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a report on Thursday, January 4th. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Monday. Finally, Guggenheim assumed coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. Twelve investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, Pfizer has a consensus rating of “Hold” and a consensus target price of $36.88.

Pfizer Stock Down 1.1 %

Shares of NYSE:PFE traded down $0.27 during midday trading on Wednesday, reaching $25.42. The company’s stock had a trading volume of 43,603,051 shares, compared to its average volume of 42,571,469. The firm has a 50 day moving average of $27.23 and a 200-day moving average of $28.79. The firm has a market capitalization of $143.94 billion, a P/E ratio of 71.36, a PEG ratio of 1.18 and a beta of 0.61. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 12-month low of $25.26 and a 12-month high of $41.33.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. During the same period in the prior year, the firm posted $1.14 EPS. Pfizer’s revenue for the quarter was down 41.3% on a year-over-year basis. On average, research analysts anticipate that Pfizer Inc. will post 2.22 earnings per share for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.